expressed in hematopoietic progenitor cells. FLT 3 gene mutations are reported in~ 30% of
acute myeloid leukemia cases. FLT 3 kinase domain mutation F691L is one of the common
causes of acquired resistance to the FLT 3 inhibitors including quizartinib. MZH 29 and
crenolanib were previously reported to inhibit FLT 3 F691L. However, crenolanib was
reported for the moderate inhibition. We found that Glu661and Asp829 were the most …